Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This mechanistic trial compared the pharmacodynamics and safety of lixisenatide and liraglutide in combination with optimized insulin glargine with/without metformin in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration. The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030–0430 h). Changes from baseline in gastric emptying, 24-h plasma glucose profile, HbA1c, fasting plasma glucose (FPG), 24-h ambulatory heart rate and blood pressure, amylase and lipase levels, and adverse events (AEs) were also assessed. RESULTS: In total, 142 patients were randomized and treated. Lixisenatide 20 µg achieved greater reductions of AUC PPG0030−0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, −6.0 [−7.8] h ⋅ mmol/L [−108.3 (−140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and −4.6 [−6.3] h ⋅ mmol/L [−83.0 (−114.2) h ⋅ mg/dL] vs. liraglutide 1.8 mg; P < 0.001 for both), and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons). FPG was unchanged in all treatment arms. At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively. At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001). Occurrence of symptomatic hypoglycemia was higher with lixisenatide; gastrointestinal AEs were more common with liraglutide. Lipase levels were significantly increased from baseline with liraglutide 1.2 and 1.8 mg (marginal mean ± SE increase 21 ± 7 IU/L for both; P < 0.05). CONCLUSIONS: Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [51]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Cited by
Items 101–200 of 282
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
Nauck, M. A., Mirna, A. E. A., & Quast, D. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14988 · Cited by 32
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Mizubuti, G. B., Ho, A. M. ‐., da Silva, L. M., & Phelan, R. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001348 · Cited by 44
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 39
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 37
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13063 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Kumarathurai, P., Anholm, C., Fabricius-Bjerre, A., Nielsen, O. W., Kristiansen, O., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001275 · Cited by 39
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Self-citationZang, L., Liu, Y., Geng, J., Luo, Y., Bian, F., Lv, X., Yang, J., Liu, J., Peng, Y., Li, Y., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12674 · Cited by 36
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“[113] The different mechanisms of action and safety profiles should be taken into consideration when electing the most appropriate treatment for a given patient.[6,114] Mealtime glucose excursions contribute to overall glycemic control and is a primary target to improve HbA1c levels.”
BackgroundCardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Valentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 37
Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Monami, M., Dicembrini, I., Nreu, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1054-2 · Cited by 35
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31
de la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0531-7 · Cited by 31
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 31
van Raalte, D. H., Bunck, M. C. M., Smits, M. M., Hoekstra, T., Cornér, A., Diamant, M., Eliasson, B., Marja-RiittaTaskinen, Heine, R. J., Smith, U., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0286 · Cited by 31
Wysham, C., Bonadonna, R. C., Aroda, V. R., Puig‐Domingo, M., Kapitza, C., Stager, W., Yu, C. H., Niemoeller, E., Souhami, E., Bergenstal, R. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12961 · Cited by 31
Self-citationOwens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 31
Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists
Raven, L. M., Stoita, A., Feller, R. B., Brown, C., & Greenfield, J. R. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.07.016 · Cited by 30
Stevens, J. E., Buttfield, M., Wu, T., Hatzinikolas, S., Pham, H., Lange, K. M., Rayner, C. K., Horowitz, M., & Jones, K. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13864 · Cited by 29
Jalleh, R., Pham, H., Marathe, C. S., Wu, T., Buttfield, M. D., Hatzinikolas, S., Malbert, C. H., Rigda, R. S., Lange, K., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29
Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
“It is well established that short-acting GLP-1 receptor agonist induces delayed gastric emptying,(23) whereas the long-acting GLP-1 receptor agonist liraglutide induces delayed gastric emptying in people with type 2 diabetes or obesity.(9,10,24) In type 1 diabetes, Dejgaard et al.”
BackgroundTargeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
Meier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle‐Stephan, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 24
Self-citationGu, J., Xin, M., Guo, Y. P., Wang, L., Zheng, H., Liu, Y., Wu, B., & Wang, D. (2016) · Scientific Reports · doi:10.1038/srep32714 · Cited by 26
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Li, X., Jin, Y., Feng, X.-Y., Wang, R.-C., Chen, J.-P., & Lu, B. (2025) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2025.111871 · Cited by 25
Feher, M., Vega-Hernandez, G., Mocevic, E., Buysse, B., Myland, M., Power, G. S., Nystrup Husemoen, L. L., Kim, J., & Witte, D. R. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0241-z · Cited by 23
Role of Point-of-Care Gastric Ultrasound in Advancing Perioperative Fasting Guidelines
Razak, A., Baburyan, S., Lee, E., Costa, A., & Bergese, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14212366 · Cited by 25
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Yin, T., Bi, Y., Li, P., Shen, S., Xiong, X.-L., Gao, L., Jiang, C., Wang, Y., Feng, W., & Zhu, D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0412-6 · Cited by 25
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
Nauck, M. A., & Meier, J. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30043-7 · Cited by 24
Self-citationSafety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Wu, T., Rayner, C. K., & Horowitz, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0164 · Cited by 24
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
“RAs show greater reductions in PPG versus longer-acting agents, and have greater effects on slowing gastric emptying.(2) Given their high glucose-lowering efficacy, association with weight loss, low risk of hypoglycaemia,(3) capacity to reduce cardiovascular risk factors,(4) and beneficial effect on multiple pathophys…”
BackgroundVlaeminck, N., de Putte, P. B. C. V., Dekeyser, M., Baert, N., Wallyn, A., Vernieuwe, L., Smitz, C. J., Wouters, K., Cauwenberghe, J. V., & Saldien, V. (2026) · Anaesthesia · doi:10.1111/anae.70129 · Cited by 23
Rosenstock, J., Handelsman, Y., Vidal, J., Ampudia‐Blasco, F. J., Giorgino, F., Liu, M., Perfetti, R., & Meier, J. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13462 · Cited by 23
Self-citationAspiration risk with glucagon‐like peptide 1 ( GLP ‐1) agonists
Marroquin‐Harris, M., & Olesnicky, B. (2023) · Anaesthesia · doi:10.1111/anae.16099 · Cited by 20
Liu, M. R., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15724 · Cited by 22
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
Raven, L. M., Brown, C., & Greenfield, J. R. (2024) · Medical Journal of Australia · doi:10.5694/mja2.52170 · Cited by 21
“9 Although it has also been suggested that the effect of GLP-1 RAs on gastric emptying may lessen with prolonged exposure, there is limited evidence to support this.”
BackgroundBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Parkman, H. P., Rim, D. S., Anolik, J. R., Dadparvar, S., & Maurer, A. H. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.266800 · Cited by 20
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
van Raalte, D. H., & Verchere, C. B. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.04.009 · Cited by 19
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
Tougaard, R. S., Jorsal, A., Tarnow, L., Hansson, N. H., Kistorp, C., Schou, M., Nielsen, R. R., Flyvbjerg, A., Videbæk, L. M., Mølgaard, H., et al. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1751873 · Cited by 19
Ueberberg, S., Jütte, H., Uhl, W. H., Schmidt, W. E., Nauck, M. A., Montanya, E., Tannapfel, A., & Meier, J. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12766 · Cited by 19
Self-citationGrosicki, G. J., Kim, J., Fielding, F., Jasinski, S. R., Chapman, C., von Hippel, W., & Holmes, K. E. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00809.2024 · Cited by 18
Bonadonna, R. C., Blonde, L., Antsiferov, M. B., Berria, R., Gourdy, P., Hatunic, M., Mohan, V., & Horowitz, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2897 · Cited by 18
Goldman, J. D., & Trujillo, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717281 · Cited by 18
Zhao, Y. M., Zhao, W., Bu, H., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000032892 · Cited by 17
Nerild, H. H., Brønden, A., Gether, I. M., Hellmann, P. H., Baekdal, M., Gillum, M. P., Svenningsen, J. S., Hartmann, B., Rathor, N., Angelene, H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15017 · Cited by 17
Yin, M., Song, Y., Guo, S., Zhang, X., Sun, K., Li, Y., & Shi, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01307 · Cited by 16
Johnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
Glycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Pioneering oral peptide therapy for patients with type 2 diabetes
Nauck, M. A., & Meier, J. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30182-2 · Cited by 15
Self-citationHayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 15
Fano, M. D., Porcellati, F., Fanelli, C. G., Corio, S., Mazzieri, A., Lucidi, P., Bolli, G. B., & Bassotti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110828 · Cited by 15
Salt and hypertension in diabetes
Uzu, T. (2017) · Diabetology International · doi:10.1007/s13340-017-0305-3 · Cited by 15
Raccah, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.007 · Cited by 15
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Lu, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00914-9 · Cited by 15
Inman, T. R., Plyushko, E., Austin, N. P., & Johnson, J. L. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818763698 · Cited by 15
Ma, J., & Vella, A. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00324 · Cited by 14
Østergaard, L., Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1313109 · Cited by 14
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
Tonneijck, L., Muskiet, M. H. A., Twisk, J. W. R., Kramer, M. H. H., Danser, A. H. J., Joles, J. A., Smits, M. M., & van Raalte, D. H. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10740 · Cited by 13
Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression
Ramadan, N. M., Malek, H. A., Rahman, K. A., El-Kholy, E., Shaalan, D., & Elkashef, W. F. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1162-8196 · Cited by 13
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Ferrannini, E., Niemoeller, E., DEX, T. A., Servera, S., & Mari, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14688 · Cited by 12
WANG, Q., Cui, Q., Xu, Y., Prud’homme, G. J., Yang, Y., Zhu, D., Li, Y., Yang, Y., & Li, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16452 · Cited by 12
Modi, R., Rye, P., Cawsey, S., Birch, D. W., & Sharma, A. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3249-1 · Cited by 12
RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
Quinn, J. A., Welch, K. M., Fujino, E., Rosado, C. A. J., An, X., Schoenherr, J. W., & Gouker, L. N. (2025) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2025.111776 · Cited by 11
Quddos, F., Fowler, M., Bovo, A. C. D. L., Elbash, Z., Tegge, A. N., Gatchalian, K. M., Kablinger, A. S., DiFeliceantonio, A. G., & Bickel, W. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-17927-w · Cited by 11
Lixisenatide: A New Option for Managing Type 2 Diabetes
Newsome, J. S. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517711958 · Cited by 11
Meier, J. J., Schenker, N., Kahle, M., Schliess, F., Kapitza, C., & Menge, B. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12968 · Cited by 11
Self-citationBallav, C., Dhere, A., Kennedy, I., Agbaje, O. F., White, S. J., Franklin, R. H., Hartmann, B., Holst, J. J., Holman, R. R., & Owen, K. R. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.130 · Cited by 10
Patoulias, D., Papadopoulos, C. E., Siskos, F., Stavropoulos, K., & Doumas, M. N. (2021) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000537 · Cited by 10
Shi, Y., Liu, L., Yin, M., Zhao, Z., Liang, Y., Sun, K., & Li, Y. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2104296 · Cited by 10
Zhang, Q.-M., Fan, Y., Liu, X., Zhang, M., Zhang, J., Du, Q., Kang, L., & Chen, L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01661-z · Cited by 9
Rayner, C. K., Jones, K. L., Wu, T., & Horowitz, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12822 · Cited by 9
SKOLNIK, N., Hinnen, D., Kiriakov, Y., MAGWIRE, M. L., & White, J. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0048 · Cited by 9
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico
Roca-Rodríguez, M. M., Muros de Fuentes, M. T., Piédrola-Maroto, G., Quesada-Charneco, M., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2017) · Atención Primaria · doi:10.1016/j.aprim.2016.06.009 · Cited by 8
Winkler, G., Hajós, P., & Kis, J. T. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31615 · Cited by 8
Irizaga, G., Domenech, P. F., Camiño, E. B., & Cardoso, G. A. (2024) · Revista Chilena de Anestesia · doi:10.25237/revchilanestv53n1-06 · Cited by 8
Hodgson, J. A., Rivera-Rodriguez, H., Wu, P. E., Udani, J., & Weiss, J. (2024) · A&A Practice · doi:10.1213/xaa.0000000000001762 · Cited by 8
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Metadata
- Authors
- Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C.
- Affiliations
- St. Josef-Hospital (DE)
- Medical City Dallas Hospital (US)
- Sanofi (France) (FR)
- Profil Institute for Metabolic Research (DE)
- Profil, Mainz, Germany
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-17
- Volume
- 38
- Issue
- 7
- Pages
- 1263-1273
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2103274121
- Cited by
- 262
- References
- 50
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 21 · 2023: 18 · 2022: 7 · 2021: 18 · 2020: 23 · 2019: 26 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 17
- FWCI
- 34.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, liraglutide, type 2 diabetes, insulin glargine, metformin, postprandial glucose control, gastric emptying, incretin-based therapy, pharmacodynamics, HbA1c, fasting blood glucose, heart rate, blood pressure, amylase and lipase, drug safety, combination therapy, pharmacokinetics
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Gastric Emptying, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.